PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
September 19, 2025Catheterization and Cardiovascular InterventionsOpen Access

One‐Year Outcomes of Short‐Term Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Drug‐Eluting Stents: A Meta‐Analysis of Randomized Clinical Trials

View Full Paper
Ask AI
Bookmark
Share

Authors

TFThomas FretzSDSrikiran DasariJSJohn Sakaleros

Discussion

Loading...

Member takes

Overview

Meta-analysis finds shorter dual antiplatelet therapy duration safe in patients post-PCI, suggesting benefits for major adverse events.

Key Points

  • Shorter duration of dual antiplatelet therapy led to a significant decrease in net adverse clinical events at one year.
  • The risk ratio for net adverse clinical events was 0.80, indicating statistical significance with p < 0.001.
  • The study reviewed results from 13 randomized clinical trials covering over 53,000 patients who underwent PCI.
  • A 3-month duration of dual antiplatelet therapy showed preferable outcomes compared to traditional longer durations.

Cite This Study

Fretz et al. (2025) studied this question.

synapsesocial.com/papers/68d43c81713b0b5dfea7bfe5https://doi.org/10.1002/ccd.70163
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Short- Versus Standard-Duration Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis2026
  2. 2Shorter vs. Standard Duration of Dual Antiplatelet Therapy in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis2025
  3. 3Sequential administration of abbreviated (up to one month) dual antiplatelet therapy and Ticagrelor monotherapy versus standard dual antiplatelet therapy after percutaneous coronary intervention: A meta-analysis2025
  4. 4Evolution of Dual Antiplatelet Therapy in the Era of New-Generation Drug-Eluting Stents: Balancing Ischemic and Bleeding Risks2026
  5. 5Aspirin or P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention for Acute Coronary Syndromes2025 · 23 citations